Metropolis Healthcare (METROPOLIS.NS) Stock Price

Metropolis Healthcare Price

NSE·CLOSED
563.20INR-1.40 (-0.25 %)
Market closed

Over the last 9 years Metropolis Healthcare grew revenue by 12.1% annually, reaching 13.31 B INR. Earnings per share have grown at 7.0% per year over the last 9 years. For Metropolis Healthcare, the net margin of 10.9% is down versus 18.3% a few years ago. At today's price the dividend yield works out to roughly 0.71%. The payout ratio is around 4% of earnings. The consensus 12-month price target for Metropolis Healthcare is 2,314.38 INR, about 310.9% above where the stock trades today. Of 24 analysts, 18 rate the stock a buy — an overall Buy consensus. The stock trades about 34% above its 52-week low.

Metropolis Healthcare stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Metropolis Healthcare over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Metropolis Healthcare stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Metropolis Healthcare's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Metropolis Healthcare Stock Price History
DateMetropolis Healthcare Price
8/7/2026563.20 INR
8/6/2026564.60 INR
8/5/2026576.75 INR
8/4/2026587.65 INR
7/31/2026582.45 INR
7/30/2026593.85 INR
7/29/2026591.60 INR
7/28/2026585.40 INR
7/24/2026570.25 INR
7/23/2026572.25 INR
7/22/2026570.10 INR
7/21/2026568.80 INR
7/20/2026573.75 INR
7/17/2026565.00 INR
7/15/2026571.65 INR
7/14/2026559.20 INR
7/13/2026564.70 INR
7/10/2026567.95 INR
7/9/2026560.05 INR
7/8/2026549.35 INR
7/7/2026575.50 INR
7/6/2026573.55 INR
7/3/2026555.55 INR
7/2/2026544.30 INR
7/1/2026541.60 INR
6/30/2026540.15 INR
6/29/2026523.80 INR
6/25/2026543.35 INR
6/24/2026553.20 INR
6/23/2026543.25 INR
6/22/2026540.50 INR
6/19/2026546.15 INR
6/18/2026553.20 INR
6/17/2026551.60 INR
6/16/2026530.45 INR
6/15/2026528.70 INR
6/12/2026523.85 INR
6/11/2026520.85 INR
6/10/2026523.20 INR
6/9/2026535.55 INR
6/8/2026529.65 INR
6/5/2026550.00 INR
6/4/2026544.15 INR
6/3/2026536.15 INR
6/2/2026541.50 INR
6/1/2026542.55 INR
5/29/2026542.00 INR
5/27/2026546.00 INR
5/26/2026530.55 INR
5/25/2026518.25 INR
5/22/2026519.70 INR
5/21/2026529.50 INR
5/20/2026510.30 INR
5/19/2026508.40 INR
5/18/2026507.40 INR
5/15/2026528.85 INR
5/14/2026540.70 INR
5/13/2026548.00 INR
5/12/2026548.10 INR
5/11/2026559.90 INR
5/8/2026549.50 INR
5/7/2026505.60 INR
5/6/2026506.40 INR
5/5/2026506.30 INR
5/4/2026492.40 INR
5/1/2026476.50 INR
4/30/2026476.50 INR
4/29/2026478.80 INR
4/28/2026480.85 INR
4/27/2026476.50 INR
4/24/2026467.10 INR
4/23/2026472.20 INR
4/22/2026476.65 INR
4/21/2026484.30 INR
4/20/2026475.40 INR
4/17/2026471.70 INR
4/16/2026472.25 INR
4/15/2026477.55 INR
4/13/2026462.35 INR
4/10/2026468.10 INR
4/9/2026456.90 INR
4/8/2026456.00 INR
4/7/2026434.40 INR
4/6/2026430.75 INR
4/2/2026421.75 INR
4/1/2026421.65 INR
3/30/2026435.00 INR
3/27/2026430.50 INR
3/25/2026437.00 INR
3/24/2026439.70 INR
3/23/2026442.40 INR
3/20/2026442.00 INR
3/19/2026456.25 INR
3/18/2026467.50 INR
3/17/2026465.00 INR
3/16/2026457.90 INR
3/13/2026452.50 INR
3/12/2026455.75 INR
3/11/2026459.50 INR
3/10/2026452.80 INR
3/9/2026446.25 INR
3/6/2026446.48 INR
3/5/2026448.35 INR
3/4/2026461.38 INR
3/2/2026463.80 INR
2/27/2026467.33 INR
2/26/2026472.58 INR
2/25/2026470.03 INR
2/24/2026473.00 INR
2/23/2026487.00 INR
2/20/2026467.00 INR
2/19/2026473.75 INR
2/18/2026481.25 INR
2/17/2026482.50 INR
2/16/2026484.00 INR
2/13/2026485.25 INR
2/12/2026494.50 INR
2/11/2026499.00 INR
2/10/2026497.53 INR
2/9/2026498.25 INR
2/6/2026496.28 INR
2/5/2026492.25 INR
2/4/2026478.73 INR
2/3/2026474.65 INR
2/2/2026478.50 INR
2/1/2026475.00 INR
1/30/2026453.15 INR
1/29/2026452.25 INR
1/28/2026456.25 INR
1/27/2026457.50 INR
1/23/2026447.80 INR
1/22/2026469.43 INR
1/21/2026484.25 INR
1/20/2026470.25 INR
1/19/2026478.83 INR
1/16/2026474.00 INR
1/14/2026469.18 INR
1/13/2026477.55 INR
1/12/2026471.50 INR
1/9/2026487.73 INR
1/8/2026478.75 INR
1/7/2026496.50 INR
1/6/2026505.00 INR
1/5/2026514.48 INR
1/2/2026486.25 INR
1/1/2026471.25 INR
12/31/2025480.28 INR
12/30/2025461.25 INR
12/29/2025472.00 INR
12/26/2025477.50 INR
12/24/2025472.00 INR
12/23/2025473.73 INR
12/22/2025472.00 INR
12/19/2025471.25 INR
12/18/2025471.75 INR
12/17/2025475.50 INR
12/16/2025477.78 INR
12/15/2025478.50 INR
12/12/2025477.50 INR
12/11/2025478.00 INR
12/10/2025481.00 INR
12/9/2025480.00 INR
12/8/2025480.10 INR
12/5/2025477.23 INR
12/4/2025481.40 INR
12/3/2025482.58 INR
12/2/2025485.25 INR
12/1/2025490.75 INR
11/28/2025482.50 INR
11/27/2025483.00 INR
11/26/2025485.25 INR
11/25/2025485.78 INR
11/24/2025487.50 INR
11/21/2025489.75 INR
11/20/2025490.10 INR
11/19/2025487.50 INR
11/18/2025482.70 INR
11/17/2025495.00 INR
11/14/2025492.55 INR
11/13/2025491.53 INR
11/12/2025492.18 INR
11/11/2025488.00 INR
11/10/2025483.75 INR
11/7/2025487.75 INR
11/6/2025495.48 INR
11/4/2025507.50 INR
11/3/2025501.85 INR
10/31/2025493.80 INR
10/30/2025489.55 INR
10/29/2025486.50 INR
10/28/2025484.25 INR
10/27/2025485.53 INR
10/24/2025476.30 INR
10/23/2025478.75 INR
10/21/2025482.00 INR
10/20/2025482.25 INR
10/17/2025484.50 INR
10/16/2025485.70 INR
10/15/2025483.00 INR
10/14/2025487.50 INR
10/13/2025493.75 INR
10/10/2025498.75 INR
10/9/2025510.00 INR
10/8/2025502.50 INR
10/7/2025525.53 INR
10/6/2025519.08 INR
10/3/2025499.18 INR
10/1/2025510.50 INR
9/30/2025506.60 INR
9/29/2025505.00 INR
9/26/2025500.28 INR
9/25/2025507.25 INR
9/24/2025525.00 INR
9/23/2025512.50 INR
9/22/2025517.50 INR
9/19/2025533.75 INR
9/18/2025512.35 INR
9/17/2025513.80 INR
9/16/2025517.50 INR
9/15/2025506.40 INR
9/12/2025514.75 INR
9/11/2025530.75 INR
9/10/2025537.50 INR
9/9/2025537.55 INR
9/8/2025545.00 INR
9/5/2025551.75 INR
9/4/2025560.00 INR
9/3/2025552.30 INR
9/2/2025544.63 INR
9/1/2025537.50 INR
8/29/2025546.08 INR
8/28/2025546.50 INR
8/26/2025542.53 INR
8/25/2025547.00 INR
8/22/2025540.75 INR
8/21/2025537.50 INR
8/20/2025544.75 INR
8/19/2025537.48 INR
8/18/2025542.50 INR
8/14/2025530.25 INR
8/13/2025532.50 INR
8/12/2025524.75 INR
8/11/2025511.25 INR
Access this data via the Eulerpool API
Get Free API Key

Metropolis Healthcare Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
11.48 B INR
2.04 B INR
1.43 B INR
Jan 1, 2024
12.08 B INR
1.95 B INR
1.28 B INR
Jan 1, 2025
13.31 B INR
1.96 B INR
1.45 B INR
Jan 1, 2026 (e)
16.50 B INR
2.93 B INR
531.32 M INR
Jan 1, 2027 (e)
18.95 B INR
3.36 B INR
703.38 M INR
Jan 1, 2028 (e)
21.59 B INR
3.83 B INR
865.53 M INR
Jan 1, 2029 (e)
24.36 B INR
4.32 B INR
1.01 B INR
Jan 1, 2030 (e)
28.43 B INR
4.71 B INR
0.00 INR

Metropolis Healthcare Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 10, 2026, 8:05 AM
 
REVENUEB INR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB INR
EBITB INR
EBIT MARGIN%
NET INCOMEB INR
NET INCOME GROWTH%
DIV.INR
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e
4.755.456.477.618.569.9812.2811.4812.0813.3116.5018.9521.5924.3628.43
–14.5818.8017.6212.5216.5223.09-6.525.1810.2323.9814.8313.9212.8216.71
71.4373.0775.0475.0473.8972.9875.8676.1177.4477.6077.6077.6077.6077.6077.60
3.403.984.865.716.337.289.328.749.3510.3312.8114.7116.7518.9022.06
1.111.361.621.801.732.432.822.041.951.962.933.363.834.324.71
23.3724.9325.0823.6920.1924.3422.9317.7416.1514.6917.7517.7517.7517.7516.57
0.771.021.041.201.271.832.141.431.281.450.530.700.871.01–
–32.292.5615.266.0043.7516.99-33.30-10.5013.38-63.3532.3923.0416.99–
––––4.004.004.004.002.004.002.002.002.00––
––––––––-50.00100.00-50.00––––
50.2050.2049.9050.0050.4051.1651.4151.3751.3951.4951.4951.4951.4951.4951.49
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Metropolis Healthcare generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Metropolis Healthcare retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Metropolis Healthcare's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Metropolis Healthcare has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Metropolis Healthcare's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Metropolis Healthcare stock margins

The Metropolis Healthcare margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Metropolis Healthcare. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Metropolis Healthcare.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
72.98 %
24.34 %
18.35 %
Jan 1, 2022
75.86 %
22.93 %
17.44 %
Jan 1, 2023
76.11 %
17.74 %
12.44 %
Jan 1, 2024
77.45 %
16.16 %
10.58 %
Jan 1, 2025
77.60 %
14.70 %
10.89 %
Jan 1, 2026 (e)
77.60 %
17.75 %
3.22 %
Jan 1, 2027 (e)
77.60 %
17.75 %
3.71 %
Jan 1, 2028 (e)
77.60 %
17.75 %
4.01 %

Metropolis Healthcare Stock Revenue, EBIT, Earnings per Share

The Metropolis Healthcare earnings per share therefore indicates how much revenue Metropolis Healthcare has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
48.77 INR
11.87 INR
8.95 INR
Jan 1, 2022
59.73 INR
13.70 INR
10.41 INR
Jan 1, 2023
55.88 INR
9.91 INR
6.95 INR
Jan 1, 2024
58.75 INR
9.49 INR
6.22 INR
Jan 1, 2025
64.63 INR
9.50 INR
7.04 INR
Jan 1, 2026 (e)
80.13 INR
14.23 INR
2.58 INR
Jan 1, 2027 (e)
92.01 INR
16.33 INR
3.42 INR
Jan 1, 2028 (e)
104.82 INR
18.61 INR
4.20 INR

Metropolis Healthcare business model & stock analysis

Metropolis Healthcare Ltd is a multinational provider of diagnostic and healthcare services based in Mumbai, India. The company has a presence in 27 countries worldwide and operates over 100 laboratories, including branches in the USA, Middle East, Africa, and Asia. The company was founded in 1980 and has since achieved an impressive growth rate.

Metropolis Healthcare SWOT Analysis

Strengths

Metropolis Healthcare Ltd possesses several strengths that provide it with a competitive edge:

  • Strong market presence and brand recognition in the healthcare industry.
  • Extensive network of diagnostic centers and laboratories across multiple locations.
  • Wide range of diagnostic tests and services offered, catering to various medical specialties.
  • Advanced technology and equipment, enabling accurate and efficient diagnosis.
  • Well-trained and experienced workforce with expertise in different medical fields.

Weaknesses

Despite its strengths, Metropolis Healthcare Ltd also faces certain weaknesses that need to be addressed:

  • Dependency on third-party laboratories for certain specialized tests, limiting control over quality and turnaround time.
  • Relatively high pricing compared to some competitors, potentially impacting market share.
  • Limited international presence, offering fewer opportunities for global expansion.

Opportunities

Metropolis Healthcare Ltd operates in an industry that presents several opportunities for growth and development:

  • Rising demand for quality healthcare services due to increasing awareness and focus on preventive health.
  • Expanding healthcare infrastructure in emerging markets, creating potential for new centers and partnerships.
  • Technological advancements opening up avenues for innovative diagnostic solutions.
  • Potential for strategic alliances and collaborations with hospitals, clinics, and healthcare providers.

Threats

Metropolis Healthcare Ltd operates in a dynamic environment that exposes it to certain threats:

  • Fierce competition from established players as well as new entrants in the healthcare industry.
  • Regulatory challenges and changes impacting the pricing and reimbursement of diagnostic tests.
  • Economic fluctuations and instability affecting consumer spending on healthcare services.
  • Technological disruptions making certain diagnostic tests obsolete or less relevant.

Metropolis Healthcare Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Metropolis Healthcare historical P/E ratio, EBIT multiple, and P/S ratio

Metropolis Healthcare annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Metropolis Healthcare shares outstanding

The number of shares of Metropolis Healthcare was 205.97 M in 2025. This indicates how many shares Metropolis Healthcare is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
204.64 M Stocks
Jan 1, 2022
205.66 M Stocks
Jan 1, 2023
205.48 M Stocks
Jan 1, 2024
205.58 M Stocks
Jan 1, 2025
205.97 M Stocks
Jan 1, 2026 (e)
205.97 M Stocks
Jan 1, 2027 (e)
205.97 M Stocks
Jan 1, 2028 (e)
205.97 M Stocks

Metropolis Healthcare stock splits

In Metropolis Healthcare's history, there have been no stock splits.

Metropolis Healthcare Dividend History

6 years of dividend payments

YearAnnual DividendYoY ChangePayments
20254.00INR↑ 300.0%1×
Nov 11, 20254.00INR 0.0%1/1
20241.00INR↓ 91.7%—
202312.00INR↑ 50.0%2×
20228.00INR 0.0%1×
20218.00INR 0.0%1×
20208.00INR—1×

Metropolis Healthcare dividend history and estimates

In 2025, Metropolis Healthcare paid a dividend amounting to 4.00 INR. Dividend means that Metropolis Healthcare distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021 (e)
8.00 INR
-4.00 INR
Jan 1, 2022 (e)
8.00 INR
-4.00 INR
Jan 1, 2023 (e)
12.00 INR
-8.00 INR
Jan 1, 2024 (e)
1.00 INR
1.00 INR
Jan 1, 2025 (e)
0.00 INR
4.00 INR
Jan 1, 2026 (e)
1.00 INR
1.00 INR
Jan 1, 2027 (e)
0.00 INR
2.00 INR
Jan 1, 2028 (e)
0.00 INR
2.00 INR

Metropolis Healthcare dividend payout ratio

In 2025, Metropolis Healthcare had a payout ratio of 3.55%. The payout ratio indicates the percentage of the company's profits that Metropolis Healthcare distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
5.59 %
Jan 1, 2022
4.80 %
Jan 1, 2023
10.79 %
Jan 1, 2024
6.38 %
Jan 1, 2025
3.55 %
Jan 1, 2026 (e)
19.38 %
Jan 1, 2027 (e)
14.64 %
Jan 1, 2028 (e)
11.90 %

Current Metropolis Healthcare forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.44 %
Buy
75.00 % (18)
Hold
8.33 % (2)
Sell
16.67 % (4)
12M Price Target
2,314.38
Last Price
563.20
Currency
INR
12M Return Potential
310.93 %
LTM Return
0 %

Metropolis Healthcare Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/14/20248.72INR-3.16 BINR-2024 Q4
2/8/20247.70INR-3.02 BINR-2024 Q3

EESG©

Eulerpool ESG Scorecard© for the Metropolis Healthcare stock

90/100
98
Environment
97
Social
75
Governance
E

Environment

20
Scope 1 - Direct Emissions132.12
Scope 2 - Indirect emissions from purchased energy9,267.939
Scope 3 - Indirect emissions within the value chain2,387.152
Total CO₂ emissions9,400.059
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees45
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Metropolis Healthcare shareholder structure

% Name
30.47311%
Metz Advisory LLP
Metz Advisory LLP
11.12733%
Shah (Duru Sushil)
Shah (Duru Sushil)
9.78483%
HDFC Asset Management Co., Ltd.
HDFC Asset Management Co., Ltd.
7.23461%
Shah (Sushil Kanubhai)
Shah (Sushil Kanubhai)
3.84364%
UTI Asset Management Co. Ltd.
UTI Asset Management Co. Ltd.
3.24727%
Tata Asset Management Ltd.
Tata Asset Management Ltd.

Metropolis Healthcare Beneficial Ownership Filings (SEC 13D/G)

Free Float
51.1%
Float Shares
-
Shares Outstanding
-

Metropolis Healthcare Executives and Management Board

21 members · avg. age 58 · 24 % women

SC

Mr. Surendran Chemmenkottil

Chief Executive Officer

23.34 M INR

Management

SP

Mr. Sameer Patel

Chief Financial Officer

–
NS

Dr. Nilesh Shah

President Internal Assurance and Advisor to Chief Executive Officer · since 2024

–
DS

Ms. Diya Suri

Chief People Officer

–
PS

Mr. Pinakin Shah

Chief Information Officer

–
MM

Mr. Mohan Menon

Chief Marketing Officer

–
KC

Dr. Kirti Chadha

Chief Scientific Officer, Innovation Officer and Group Head CSR · since 2024

–

Board of Directors

AS

Ms. Ameera Shah (45)

Executive Chairman of the Board · since 2024

58.92 M INR
SS

Dr. Sushil Shah (78)

Non-Executive Non-Independent Director · since 2024

6.91 M INR
SR

Mr. Subramanian Ranganathan

Non-Executive Independent Director

2.08 M INR
VG

Mr. Vivek Gambhir (56)

Non-Executive Independent Director

1.93 M INR
SB

Mr. Sanjay Bhatnagar (63)

Non-Executive Independent Director

1.48 M INR
RK

Mr. Rehan Khan

Non-Executive Director

–

Frequently asked questions about Metropolis Healthcare

Metropolis Healthcare Ltd is a leading provider of diagnostic services in India. Their business model revolves around offering a comprehensive range of medical diagnostic tests and services to patients, healthcare providers, and corporate clients. Metropolis operates through a hub-and-spoke model, with a network of laboratories and patient service centers strategically located across multiple cities. They focus on delivering accurate and timely test results using advanced technology and expert medical professionals. With a strong emphasis on quality and customer satisfaction, Metropolis Healthcare Ltd aims to improve healthcare outcomes by enabling early detection and effective treatment of diseases.

Metropolis Healthcare Ltd is primarily active in the healthcare industry.

The main competitors of Metropolis Healthcare Ltd in the market include Dr. Lal PathLabs Ltd, Thyrocare Technologies Ltd, and SRL Diagnostics.

Metropolis Healthcare Ltd is a renowned company in the healthcare sector with an impressive history and background. Founded in 1980, Metropolis Healthcare has grown to become one of the leading diagnostic companies in India, catering to the diverse needs of patients and healthcare providers. With a focus on delivering accurate, reliable, and timely diagnostics services, Metropolis has expanded its footprint across 7 countries, including India, South Africa, Kenya, and Sri Lanka. The company's commitment to quality, advanced technology, and expert medical professionals has earned it a strong reputation in the industry. Metropolis Healthcare Ltd continues to revolutionize the diagnostics landscape, ensuring better healthcare outcomes for individuals and communities.

Metropolis Healthcare Ltd has achieved several significant milestones. It has expanded its presence to over 125 cities and towns in India, establishing itself as a leading diagnostic company in the country. The company has received accreditation from the National Accreditation Board for Testing and Calibration Laboratories (NABL) for its laboratories across India. Metropolis Healthcare Ltd is also the first laboratory network to be recognized by the National Reference Laboratory in the United Arab Emirates. Furthermore, the company has been awarded the Best Diagnostic Service Provider of the Year by Frost & Sullivan in 2020. These achievements highlight Metropolis Healthcare Ltd's commitment to quality services and its position as a pioneering player in the healthcare industry.

Metropolis Healthcare Ltd is primarily present in India.

Metropolis Healthcare Ltd represents values of excellence, integrity, and innovation in the healthcare industry. With a strong corporate philosophy centered around patient-centricity and quality diagnostics, the company aims to provide accurate and reliable diagnostic solutions to improve patient outcomes. Metropolis Healthcare Ltd is committed to delivering world-class pathology and laboratory services with a focus on advanced technology, skilled professionals, and continuous research and development. As a leading player in the diagnostic industry, the company's goal is to redefine standards and set new benchmarks in healthcare. Through its unwavering commitment to excellence, Metropolis Healthcare Ltd strives to make a positive impact on people's lives.

Analysts currently set an average price target of 2,312.28 INR for the Metropolis Healthcare stock (median: 2,314.38 INR), implying +310.6 % versus the latest price. The consensus is based on 24 analyst ratings.

Metropolis Healthcare Analyst Price Targets 2026

24 analysts currently rate the Metropolis Healthcare stock: 19 recommend buying, 3 holding and 2 selling. For 2026, analysts expect Metropolis Healthcare to generate revenue of 16.50 B INR and earnings per share of 2.58 INR.

Metropolis Healthcare Analyst Price Targets 2026

Converted at the current exchange rate, the Metropolis Healthcare share trades at 5.12 EUR (563.20 INR).

Metropolis Healthcare Ltd is a leading provider of diagnostic services in India and worldwide. The company was founded in Mumbai in 1980 and has since achieved an impressive track record of growth, focusing on customer needs and introducing innovative technologies and practices. Metropolis Healthcare Ltd comprises four main divisions, each tailored to customer needs and different markets. These divisions include general pathology, oncology, genetics, and microbiology. Each division offers a wide range of tests tailored to specific customer needs. Metropolis Healthcare's general pathology segment includes a wide range of tests for various diseases such as diabetes, liver diseases, kidney disorders, and hormonal disorders. The company utilizes advanced technologies such as polymerase chain reaction (PCR) and immunohistochemistry for precise and rapid diagnoses. Metropolis Healthcare's oncology segment provides tests for various types of cancer. The company has established an extensive network of tumor centers and specialists for cancer diagnosis and treatment. The tests include blood tests, biopsies, and imaging procedures such as computer or magnetic resonance imaging. Metropolis Healthcare's genetics segment offers genetic tests for various diseases such as cancer, heart diseases, or rare genetic disorders. The company is a leader in the application of next-generation sequencing (NGS) for precise genetic diagnoses. Metropolis Healthcare's microbiology segment specializes in infectious diseases. The company has laboratories equipped with state-of-the-art technologies for conducting tests for diseases such as tuberculosis, malaria, dengue fever, and HIV. Metropolis Healthcare also provides a wide range of products needed for disease diagnostics. These products include instruments, test kits, and consumables. The company has partnerships with globally leading companies such as Roche Diagnostics, Siemens Healthcare, and Thermo Fisher Scientific to supply their customers with the latest products and technologies. Metropolis Healthcare's business model is based on a combination of high-quality services, innovative technology, and customer orientation. The company has a strong presence in India and is also expanding into international markets such as Africa, Southeast Asia, and Europe. Metropolis Healthcare has also recently built an increasing presence in telemedicine and digital diagnostics to meet the needs of customers in remote or underserved areas. Overall, Metropolis Healthcare Ltd offers a wide range of diagnostic services and products. The company has established itself as a leading provider of diagnostic services in India and worldwide through its business model and services.

The expected revenue of Metropolis Healthcare is 16.50 B INR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Metropolis Healthcare is 531.32 M INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Metropolis Healthcare is currently 218.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Metropolis Healthcare stock.

The price-to-sales ratio (P/S) of Metropolis Healthcare is currently 7.03. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Metropolis Healthcare stock.

The Eulerpool Quality Score for Metropolis Healthcare is 4/10.

The ISIN of Metropolis Healthcare is INE112L01020. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Metropolis Healthcare is METROPOLIS.NS. The ticker symbol is used to trade Metropolis Healthcare shares on the stock exchange.

Over the past 12 months, Metropolis Healthcare paid a dividend of 4.00 INR . This corresponds to a dividend yield of about 0.71 %. For the coming 12 months, Metropolis Healthcare is expected to pay a dividend of 2.00 INR.

The current dividend yield of Metropolis Healthcare is 0.71 %.

Metropolis Healthcare pays a dividend, distributed in the months of , , , .

Metropolis Healthcare paid dividends every year for the past 1 years.

For the upcoming 12 months, dividends amounting to 2.00 INR are expected. This corresponds to a dividend yield of 0.36 %.

Metropolis Healthcare is assigned to the 'Health' sector.

To receive the latest dividend of Metropolis Healthcare from amounting to 4 INR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Metropolis Healthcare distributed 1 INR as dividends.

The dividends of Metropolis Healthcare are distributed in INR.

All fundamentals and in-depth analysis of Metropolis Healthcare

Our stock analysis for Metropolis Healthcare stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Metropolis Healthcare. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Metropolis Healthcare Stock
Metropolis Healthcare Revenue→
Metropolis Healthcare Stock
Metropolis Healthcare Net Income→
Metropolis Healthcare Stock
Metropolis Healthcare P/E→
Metropolis Healthcare Stock
Metropolis Healthcare P/S→
Metropolis Healthcare Stock
Metropolis Healthcare EBIT→
Metropolis Healthcare Stock
Metropolis Healthcare Dividend→
Metropolis Healthcare Stock
Metropolis Healthcare Directors Dealings→
Metropolis Healthcare Stock
Metropolis Healthcare Stocks→
Metropolis Healthcare Stock
Metropolis Healthcare Market capitalization→
Metropolis Healthcare Stock
Metropolis Healthcare Debt→
Metropolis Healthcare Stock
Metropolis Healthcare Liabilities→
Metropolis Healthcare Stock
Metropolis Healthcare Equity→
Metropolis Healthcare Stock
Metropolis Healthcare AAQS→
Metropolis Healthcare Stock
Metropolis Healthcare Employees→
Metropolis Healthcare Stock
Metropolis Healthcare ROE→
Metropolis Healthcare Stock
Metropolis Healthcare ROA→
Metropolis Healthcare Stock
Metropolis Healthcare ROCE→
Metropolis Healthcare Stock
Metropolis Healthcare News→
Metropolis Healthcare Stock
Metropolis Healthcare Analyst Price Targets→

Health Stocks

Mettler-Toledo InternationalMetro Healthcare Indonesia Tbk PTMevis Medical SolutionsMetaViaMezzion Pharma CoMetaStatMGI Tech CoMetall ZugMicro Digital CoMetagenomi TherapeuticsMicro-Tech Nanjing CoMetacare CoAll Stocks A–Z →